Related Experiment Video
Updated: Apr 21, 2026
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
2.1K
Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis
Alberto Migliore1, Emanuele Bizzi, Mauro Bernardi
1Department of Rheumatology, Rheumatology Unit, S.Pietro Fatebenefratelli Hospital, Via cassia 600, 00189, Rome, Italy.
Clinical Drug Investigation
|November 13, 2014
Summary
This study compared subcutaneous anti-tumor necrosis factor alpha (TNF-alpha) agents for ankylosing spondylitis (AS). Golimumab showed the highest probability for ASAS20 response at 12 weeks compared to placebo in biologic-naive patients.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Ankylosing spondylitis (AS) treatment involves four subcutaneous anti-tumor necrosis factor alpha (TNF-alpha) agents.
- Previous studies show limited differences in effectiveness among these AS therapies.
Purpose of the Study:
- To compare the efficacy of subcutaneous anti-TNF-alpha agents in AS patients.
- To evaluate Assessment in Ankylosing Spondylitis Response Criteria 20 (ASAS20) response patterns.
Main Methods:
- A mixed-treatment comparison of randomized controlled trials (RCTs) was conducted.
- Five double-blind, placebo-controlled RCTs of etanercept, certolizumab pegol, golimumab, and adalimumab were analyzed.
- The primary endpoint was ASAS20 response at 12 weeks, analyzed using Bayesian techniques.
Main Results:
- All tested subcutaneous anti-TNF-alpha agents were more effective than placebo in achieving ASAS20 response.
- Golimumab demonstrated the highest probability of achieving ASAS20 response at 12 weeks.
- No statistically significant differences were found when directly comparing individual subcutaneous anti-TNF-alpha agents.
Conclusions:
- While no direct comparisons showed significant differences, golimumab may offer the highest probability for ASAS20 response in biologic-naive AS patients at 12 weeks.
- This analysis, based on limited RCT data, suggests golimumab as a potentially optimal choice over placebo.
More Related Videos
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
832
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
832
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
221
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
221
01:16Bioequivalence: Overview
2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
01:13Bioequivalence studies: Biowaivers
418
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
418